# K Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/k-pharma

- Industry: Pharmaceuticals
- Headquarters: Tokyo, Japan
- Website: www.kpharma.co.jp
- Total disclosed funding: $12M
- Latest round: Series C (May 24, 2022)
- Investors on record: 5

## About

Based in Tokyo, Japan, and founded in 2016, K Pharma, Inc. is a pharmaceutical company that researches, develops, and manufactures medicinal drugs and pharmaceutical products. In May 2022, K Pharma, Inc. raised JPY 1.55 billion in venture funding from DCI Partners, ICMG Partners, ITOCHU Technology Ventures, Kagoshima Development, and Keio Innovation Initiative. As of May 2022, Hiroaki Fukushima is the CEO of K Pharma, Inc.

The product line of K Pharma includes regenerative medicine and pharmaceuticals, which acts as a therapeutic tool for cerebral infarctions, and spinal cord injuries.

K Pharma plans to use its proceeds from May 2022 funding to strengthen the research and development of regenerative medicine and support the clinical trials and the company's new pharmaceutical pipelines.

## Funding rounds

- Series C, May 24, 2022, $12M — Daiwa Corporate Investment, ITOCHU Technology Ventures, Keio Innovation Initiative, Renaissance Capital Group, ICMG Partners

## Investors

- Daiwa Corporate Investment (https://capitalatlas.ai/funds/daiwa-corporate-investment) — Series C
- ITOCHU Technology Ventures (https://capitalatlas.ai/funds/itochu-technology-ventures) — Series C
- Keio Innovation Initiative (https://capitalatlas.ai/funds/keio-innovation-initiative) — Series C
- Renaissance Capital Group (https://capitalatlas.ai/funds/renaissance-capital-group) — Series C
- ICMG Partners (https://capitalatlas.ai/funds/icmg-partners) — Series C